Abbott Laboratories (ABT) announced results for the first fiscal quarter on Wednesday. Here are the main details:
Revenue for the quarter increased 17% to $7.39 billion; after excluding exchange costs and divestment, endogenous revenue for the quarter increased 6.9%. Analysts previously surveyed by Thomson Reuters (Thomson Reuters) estimated $7.29 billion.
Net profit for the quarter was US$418 million, or 23 cents per share; compared with net profit of US$419 million for the same period last year, or 24 cents per share. Adjusted earnings per share for the quarter were 59 cents, and analysts' expectations were 58 cents.
The company also expects adjusted earnings of $2.80-2.90 per share for fiscal year 2018; Wall Street analysts expect $2.86.
Abbott Pharmaceuticals fell 2% in the premarket.
By Austen Hufford; Write to Austen Hufford at Austen.Hufford@wsj.com
Copyright (c) 2018 Dow Jones Company. This article is copyrighted by Dow Jones, Inc., and may not be translated or reprinted without permission.
Revenue for the quarter increased 17% to $7.39 billion; after excluding exchange costs and divestment, endogenous revenue for the quarter increased 6.9%. Analysts previously surveyed by Thomson Reuters (Thomson Reuters) estimated $7.29 billion.
Net profit for the quarter was US$418 million, or 23 cents per share; compared with net profit of US$419 million for the same period last year, or 24 cents per share. Adjusted earnings per share for the quarter were 59 cents, and analysts' expectations were 58 cents.
The company also expects adjusted earnings of $2.80-2.90 per share for fiscal year 2018; Wall Street analysts expect $2.86.
Abbott Pharmaceuticals fell 2% in the premarket.
By Austen Hufford; Write to Austen Hufford at Austen.Hufford@wsj.com
Copyright (c) 2018 Dow Jones Company. This article is copyrighted by Dow Jones, Inc., and may not be translated or reprinted without permission.